29 results
8-K
EX-99.1
MCRB
Seres Therapeutics Inc
9 Jan 24
Regulation FD Disclosure
7:05am
al. 2020) Day 0 through 30, 64% of patients (Fig.1 black line) Pathogen abundance domination has been shown to be associated with risk of blood stream
8-K
EX-99.1
gbkkytmx87p s9
28 Jun 23
Amendments to Articles of Incorporation or Bylaws
8:00am
8-K
EX-99.2
ffmw84j4qmld3thw5
9 May 23
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
8:16am
8-K
EX-99.3
yj344j evuh4t
9 May 23
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
8:16am
PRE 14A
mk3684yw8mk
14 Apr 23
Preliminary proxy
4:30pm
8-K
EX-99.1
dcflbgb7tfhatzjbt
7 Jun 22
Regulation FD Disclosure
7:36am
8-K
EX-99.1
em0rtfjodn6sdbgv
10 Aug 20
Regulation FD Disclosure
7:31am